ERD

9.4 Safety and Immunogenicity of TBV candidates

Project: OptiMalVax

Updated at: 29-04-2024

Show more information

Project acronym OptiMalVax

VACCINE IMMUNOGENS

Project: OptiMalVax

Updated at: 29-04-2024

Show more information

Project acronym OptiMalVax

MULTIVALENT MALARIA TRANSMISSION-BLOCKING VACCINES

Project: OptiMalVax

Updated at: 29-04-2024

Show more information

Project acronym OptiMalVax

8.5 Report on immuno-efficacy of blood-stage VLP/vaccine

Project: OptiMalVax

Updated at: 21-11-2023

Show more information

Project acronym OptiMalVax

8.4 Report on safety and immunogenicity of blood-stage VLP/vaccine

Project: OptiMalVax

Updated at: 21-11-2023

Show more information

Project acronym OptiMalVax

CRISPR/Cas9-engineered inducible gametocyte producer lines as a valuable tool for Plasmodium falciparum malaria transmis...

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Contro...

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

2.2 Ability of specific liver-stage antigen expression in hepatocytes to be detected by using marker epitopes

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

1.2 Definition of 8 selected new candidate sporozoite antigens

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

4.4 Generate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPs

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

10.1 Creation of website

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies n...

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

5.4 Optimised process for biomanufacture of lead novel VLPs for GMP production

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

5.5 feasibility of enhancing the durability of protective immune responses using VLPs in microcapsules

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

7.8 Report on efficacy against sporozoite challenge of vectored prime-target immunisation combined with R21b in healthy ...

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

2.4 Utility of new prime-target immunisation approaches in liver-stage protective immunity in mice

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

5.3 Comparison of immunogenicity of lead VLPs and evidence of non-interference

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

3.2 Immunogenicity and growth inhibitory activity of the lead blood-stage bivalent VLP

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

3.1 Preferred VLP for generation of bi-valent blood-stage immunogen

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Alpha-v–containing integrins are host receptors for the Plasmodium falciparum sporozoite surface protein, TRAP

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vacci...

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

7.6 Report on efficacy against sporozoite challenge of prime-target immunisation in healthy volunteers

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Novel insights from the Plasmodium falciparum sporozoite-specific proteome by probabilistic integration of 26 studies.

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

4.2 Validation of selected novel candidate and comparison with leading antigens

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Resources

Selected filters:

9.4 Safety and Immunogenicity of TBV candidates

VACCINE IMMUNOGENS

MULTIVALENT MALARIA TRANSMISSION-BLOCKING VACCINES

8.5 Report on immuno-efficacy of blood-stage VLP/vaccine

8.4 Report on safety and immunogenicity of blood-stage VLP/vaccine

CRISPR/Cas9-engineered inducible gametocyte producer lines as a valuable tool for Plasmodium falciparum malaria transmis...

Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Contro...

Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens

2.2 Ability of specific liver-stage antigen expression in hepatocytes to be detected by using marker epitopes

1.2 Definition of 8 selected new candidate sporozoite antigens

4.4 Generate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPs

10.1 Creation of website

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum

Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites

A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies n...

Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens

5.4 Optimised process for biomanufacture of lead novel VLPs for GMP production

5.5 feasibility of enhancing the durability of protective immune responses using VLPs in microcapsules

7.8 Report on efficacy against sporozoite challenge of vectored prime-target immunisation combined with R21b in healthy ...

2.4 Utility of new prime-target immunisation approaches in liver-stage protective immunity in mice

5.3 Comparison of immunogenicity of lead VLPs and evidence of non-interference

3.2 Immunogenicity and growth inhibitory activity of the lead blood-stage bivalent VLP

3.1 Preferred VLP for generation of bi-valent blood-stage immunogen

Alpha-v–containing integrins are host receptors for the Plasmodium falciparum sporozoite surface protein, TRAP

A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response

A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vacci...

Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies

7.6 Report on efficacy against sporozoite challenge of prime-target immunisation in healthy volunteers

Novel insights from the Plasmodium falciparum sporozoite-specific proteome by probabilistic integration of 26 studies.

4.2 Validation of selected novel candidate and comparison with leading antigens